Navigation Links
Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
Date:2/13/2008

CORONA, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") has initiated an inspection of the company's Florida facilities. No information regarding the duration or outcome of the inspection is known.

Since September 2005, the Davie, Florida manufacturing facility has been under Official Action Indicated ("OAI"). During that time, Watson has continued to file Abbreviated New Drug Applications ("ANDAs") for product candidates to be manufactured at this site. However, FDA approval of pending ANDAs has been withheld pending positive resolution of the OAI status. While a resolution to the OAI status may enable product candidates to be approved, it does not ensure that any such ANDAs will be approved or, if approved, will be launched. The OAI status does not affect manufacture of products at the Davie, Florida facility that have already been approved for manufacture at that facility, nor does it affect Watson's other locations.

Watson's Davie, Florida facility was acquired in November 2006 as part of Watson's acquisition of Andrx Corporation.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the ability to timely resolve with the FDA the pending Official Action Indicated status of the Davie, Florida manufacturing facility; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... Today, True Vision Funding LLC ... formation of a new division for the purchase of sports and music entertainment ... , Clinton Portis, former Washington Redskins running back and supporter for TVF ...
(Date:3/1/2017)... ... March 01, 2017 , ... Financial Recovery Group, Inc. (FRG), is ... Nashville Summit in Nashville, Tenn. The company also is offering a special discount for ... in its 11th year, brings together the brightest minds in the healthcare industry to ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... pleased to announce the release of its 2017 update to Compass, the ... staff and physician advisors. , Suitable for standardizing both new-hire on-boarding and ...
(Date:3/1/2017)... ANGELES, CA (PRWEB) , ... March 01, 2017 , ... ... launch of her new mobile app Time & Go. , Time & Go app ... of life: career, relationships, and well-being. Efficient time management methods enable people to work ...
(Date:3/1/2017)... ... March 01, 2017 , ... “There is Comfort for the Soul”: ... the author in their all-too-brief time together, and the soul-healing comfort provided by God’s ... the creation of published author, Jerie A. Tau, a dog-loving medical professional whose work ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
(Date:3/1/2017)... 1, 2017  The Pharmaceutical Care Management Association (PCMA) ... vote to advance the nomination of Seema Verma ... Services Administrator: "The popular Medicare Part ... American health care. By offering an abundance of competing ... tools like pharmacy networks and home delivery, the program ...
(Date:3/1/2017)... -- The global  Intraoperative Neuromonitoring (IONM) market  is expected to reach ... Research, Inc. The intraoperative neuromonitoring market is anticipated to witness significant growth in ... in a wide spectrum of surgeries. Continue Reading ... ... ...
Breaking Medicine Technology: